Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/10/2026Positive
MCK
McKesson CorporationNYSEHEALTHCAREMEDICAL DISTRIBUTION
Key Statistics
Market Cap
$100.26B
P/E Ratio
23.31
EPS
$36.89
Beta
0.31
52W High
$997.90
52W Low
$670.66
50-Day MA
$813.12
200-Day MA
$839.62
Dividend Yield
0.38%
Profit Margin
1.12%
Forward P/E
19.49
PEG Ratio
1.64
About McKesson Corporation
McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.
Fundamentals
| Revenue (TTM) | $410.98B |
| Gross Profit (TTM) | $14.93B |
| EBITDA | $7.07B |
| Operating Margin | 1.35% |
| Return on Equity | 0.00% |
| Return on Assets | 4.74% |
| Revenue/Share (TTM) | $3367.33 |
| Book Value | $-36.55 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 0.24 |
| EV/Revenue | 0.262 |
| EV/EBITDA | 14.38 |
| Quarterly Earnings Growth (YoY) | -17.60% |
| Quarterly Revenue Growth (YoY) | 7.70% |
| Shares Outstanding | $116.59M |
| Float | $116.39M |
| % Insiders | 0.06% |
| % Institutions | 94.39% |
Historical Volatility
HV 10-Day
38.49%
HV 20-Day
37.22%
HV 30-Day
37.26%
HV 60-Day
31.01%
HV Rank
87.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($991.40 target)
3
Strong Buy11
Buy3
HoldLatest News
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research8/7/2026Positive
MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised
McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.
Zacks Investment Research8/6/2026Positive
MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
McKesson raises fiscal 2027 earnings guidance after pharma profit rises 19%, while specialty demand, oncology growth and disciplined spending shape the call.
Zacks Investment Research8/6/2026Positive
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/6/2026Positive
McKesson raises annual profit forecast on strong growth in specialty drug business
Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses.
Reuters8/5/2026Positive
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Barrons8/5/2026Positive
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks Investment Research8/4/2026Negative
Why McKesson (MCK) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research8/4/2026Positive
Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results?
McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.
Zacks Investment Research8/3/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MCK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026